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Edited by Beat ImhofAbstract The pro-inﬂammatory cytokine macrophage migra-
tion inhibitory factor (MIF) is induced by glucocorticoids
(GCs), but it was not previously known if MIF regulates cellular
sensitivity to GC. Here we show in GC and LPS-treated perito-
neal macrophages derived from MIF/ and wt mice that the
absence of endogenous MIF is associated with increased sensitiv-
ity to GC of TNF release. This is associated with increased
expression of mitogen-activated protein kinase (MAPK) phos-
phatase-1 (MKP-1), concomitant decreased phosphorylation of
p38 MAPK, but no eﬀect of MIF on nuclear factor jB (NF-
jB). These results demonstrate that MIF regulates GC sensitiv-
ity by phosphorylation of p38, and provides a cellular mechanism
for this observation, indicating that MKP-1 is a central target of
this regulation.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Macrophage migration inhibitory factor (MIF), a pro-
inﬂammatory cytokine, has a broad spectrum of pro-inﬂam-
matory actions. MIF has an established role in endotoxin re-
sponses, T cell activation, and leukocyte traﬃcking, and has
been implicated in the pathogenesis of common inﬂammatory
diseases including rheumatoid arthritis, colitis, multiple sclero-
sis, atheroma, psoriasis, and systemic lupus erythematosus
(SLE) [1].
In contrast to other pro-inﬂammatory cytokines that are
generally suppressed by glucocorticoids (GCs), MIF expres-
sion and secretion is increased in response to physiological
concentrations of GC. Dose dependent stimulation of MIF re-
lease by GC has now been shown to occur in a wide range of
cell types [2–5]. Evidence for endogenous GC upregulation of
MIF in vivo has also been obtained, in experimental arthritisAbbreviations: MIF, macrophage migration inhibitory factor; MAPK,
mitogen-activated protein kinase; ERK, extracellular signal-regulated
kinase; JNK, Jun N-terminal kinase; MKP-1, MAPK phosphatase-1;
GC, glucocorticoid; DEX, dexamethasone; NF-jB, nuclear factor jB;
IjBa, NF-jB inhibitor a
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doi:10.1016/j.febslet.2006.01.027[6]. Others have described posttranslational regulation of
MIF expression by exogenous GC in vivo in the rat [7]. In vivo
regulation of serum MIF by exogenous GC in humans has
been demonstrated in patients with SLE, with the observation
that serum MIF was inﬂuenced by GC administration even
after adjusting for disease activity variables [8]. Moreover,
the pro-inﬂammatory eﬀects of MIF have been shown to over-
ride the anti-inﬂammatory eﬀects of GC, in vitro and in vivo.
MIF is therefore a factor, induced by GC, which acts to limit
their eﬀectiveness. This evidence has led to the hypothesis that
MIF functions as an endogenous counter regulator of GC ef-
fects; to date, however, no data has been reported demonstrat-
ing a role of endogenous MIF in regulating GC sensitivity per
se. GC-resistance or changes in GC-sensitivity have been
widely recognised as complicating the management of chronic
inﬂammatory diseases such as asthma or chronic obstructive
pulmonary disease.
The mechanism by which MIF counter-regulates the
anti-inﬂammatory eﬀects of GC has also not been eluci-
dated. MIF has been consistently shown to activate mito-
gen-activated protein kinase (MAPK) pathways, in
particular the p38 and extracellular signal-regulated kinase
(ERK) pathway [9,10]. This suggests that reciprocal regula-
tion by MIF and GC of a factor involved in controlling
MAPK activity may underlie MIF modulation of GC
eﬀects. MAP kinase phosphatase 1 (MKP-1) is one of a
family of 11 MKPs, known to be crucial in regulating
MAPKs via dephosphorylation of the MAPK regulatory
residues. The MKPs have a unique and overlapping sub-
strate speciﬁcity towards the MAPKs (reviewed in [11]).
MKP-1 is the archetypal MKP, known to dephosphorylate
and inactivate all three MAPKs, with some cell to cell var-
iability in speciﬁcity [11]. Cells lacking MKP-1 exhibit
increased p38 and Jun N-terminal kinase (JNK) MAPK
activation [12]. Overexpression of MKP-1 substantially
attenuates the production of TNF induced by peptidoglycan
[13]. GC have recently been shown to block MAPK activity
via upregulation of MKP-1 [14–16].
Given the eﬀects of MIF on MAP kinase, the eﬀects of MIF
on GC, and the eﬀects of GC on MKP-1, MKP-1 is a candi-
date target for the mechanism of the function interaction be-
tween MIF and GC. We hypothesised that MIF would
regulate sensitivity to GC by inﬂuencing the expression of
MKP-1. In the present study, we report on the role of MIF
in the regulation of GC sensitivity, MAPK activation and
GC induction of MKP-1.blished by Elsevier B.V. All rights reserved.
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2.1. Isolation of peritoneal macrophages and cell culture
MIF/ mice were generated via homologous recombination in J1
embryonic stem cells as described previously [17]. They were main-
tained on a mixed 129/Sv C57BL/6 background. Wildtype (wt)
MIF+/+ mice, bred originally from MIF+/ littermates, were main-
tained on the same background and used as controls, as previously re-
ported [18]. MIF/ and wt mice (7–12 weeks old) were injected intra-
peritoneally with 2 ml of 3% thioglycollate. Mice were killed after 4
days and peritoneal macrophages collected by lavage with cold HBSS.
Cells were recovered by centrifugation, resuspended in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) (JRH Biosciences, Lenexa, KS)
supplemented with 5% heat inactivated fetal calf serum (FCS) (JRH
Biosciences), L-glutamine (JRH Biosciences) and penicillin/streptomy-
cin (ICN Biomedical, Aurora, OH) and plated into tissue culture
plates. Cells were allowed to adhere for 2 h, washed free of non-adher-
ent cells and maintained in DMEM containing 5% heat inactivated
FCS and penicillin/streptomycin.
Cells were treated 12 h later either with 100 ng/ml LPS [Escherichia
coli 0111.B4 (Sigma–Aldrich, St. Louis, MO)], dexamethasone (DEX)
(Sigma–Aldrich) (107–1010 M), rMIF (0.1–100 ng/ml) for 30 min,
1 h, 4 h, and 6 h. Culture conditions were chosen to avoid diﬀerences
in LPS-induced TNF release and cell activation in MIF/ cells under
serum-starved conditions (data not shown).
Anti-MIF mAb (III.D.9, kindly provided by Dr. R. Bucala, Yale
University, New Haven, CT) was produced in a mouse hybridoma sys-
tem and used at 200 lg/ml. Because of high homology of murine and
human MIF (90% identity over 115 amino acids) [19], recombinant hu-
manMIF was used. Recombinant humanMIF protein was kindly pro-
vided by Cortical Pty Ltd. (Melbourne, Australia). Brieﬂy, a human
MIF (GenBank Accession No. NM_002415.1) ORF clone IOH3502
(Invitrogen, Carlsbad, CA) was transferred into a pET41a(+) vector
(Novagen, Madison, WI) for expression in E. coli BL21(DE3). MIF
protein production was induced by 4 h treatment with 1 mM IPTG
(Fermentas, Hanover, MD) at 30 C. Cell pellets were then lysed by
sonication and freeze–thaw cycles in 50 mM sodium phosphate,
100 mM NaCl containing complete protease inhibitors (Roche, Pleas-
anton, CA). The clariﬁed lysis supernatant was puriﬁed sequentially
using a Unosphere Q column (Biorad, Palm Springs, CA), a CM-Se-
pharose FF column (Amersham, Piscataway, NJ) and dialysis. The
resulting protein was detected as a single band on a 12% NuPAGE
reducing gel (Invitrogen) in MES buﬀer and estimated to be >95%
pure. The MIF protein was conﬁrmed as full-length and of native ter-
tiary strucutre by demonstration of activity in a tautomerase assay
[20]. Endotoxin levels were less than 0.15 EU/mg.
2.2. Western blot analysis
Protein was extracted using stress lysis buﬀer containing HEPES,
MgCl2, EDTA, B-glycerophosphate, NaCl, Triton X, DTT, Na3VO4,
leupeptin, PMSF, and aprotinin (Sigma–Aldrich). Protein concentra-
tion was measured by BCA Protein assay reagent kit (Pierce Chemical,
Rockford, IL). 60–120 lg of protein (depending on the gel size) was
separated on 10% SDS–polyacrylamide electrophoresis gels and trans-
ferred to Hybond-C extra nitrocellulose membranes (Millipore, Bed-
ford, MA). The blot was incubated overnight in the appropriate
primary antibody and diluted 1:1000 in blocking buﬀer. Membranes
were stripped and serially reprobed with antibodies against phospho-
p38, phospho-JNK and phospho-ERK (Cell signaling, Beverly MA),
Ij-Ba (Santa Cruz, Santa Cruz, CA) and MKP-1 (Santa Cruz and up-
state, Lake Placid, NY). For detection, labeled anti-mouse or anti-rab-
bit antibody were used (Molecular Probes, Eugene, OR). Western blots
were scanned and densitometry ratios normalized to b-actin content
and expressed as arbitrary units (AU) using Odyssey (Li-Cor Biotech-
nology, Lincoln, NE).2.3. Real time PCR for MKP-1 and TNF
Real time polymerase chain reaction (PCR) was used to measure
murine TNF and MKP-1 mRNA. Total RNA was extracted using
TRIzol reagent (Gibco-BRL, Grand Island, NY). 1 lg of total RNA
was reverse transcribed using Superscript III reverse transcriptase
(BRL) and oligo-(dT)20. PCR ampliﬁcation was performed on a Light-
Cycler (Roche Diagnostics, Castle Hill, NSW, Australia) using SYBR
Green I (Roche), as previously described [21]. Murine TNF, MKP-1and b-actin PCR products were employed as assay standards. Ampli-
ﬁcation (40 cycles) was carried out in a total volume of 10 lL contain-
ing 1 lL dNTP mix, Taq, SYBR Green I dye, and primer-speciﬁc
nucleotide sequences for MKP-1, TNF and b-actin as described
[14,21]. Melting curve analysis and agarose gel electrophoresis was per-
formed at the end of each PCR reaction. The level of TNF and MKP-1
mRNA expression was quantitated and expressed relative to b-actin
expression. The results based on a ratio of target mRNA to b-actin
ampliﬁcation are presented as the fold induction in mRNA expression
relative to the amount present in control samples.
2.4. TNF ELISA
TNF protein was measured in cell culture supernatant from 4 h cul-
tures of thioglycolate elucidated peritoneal macrophages by sandwich
ELISA using commercially available antibodies (R&D Systems, Min-
neapolis MN). The percentage inhibition of TNF production by DEX
was calculated compared to non-DEX treated controls as follows:
(TNF concentration in culture medium of cells treated with DEX plus
LPS)/(TNF concentration in culture medium of cells treated with
LPS).
2.5. Transient transfection of peritoneal macrophages
To examine NF-jB activity in wt and MIF/ peritoneal macro-
phages, a NF-jB luciferase reporter assay using an Amaxa Nucleofec-
torII apparatus (Amaxa, Cologne, Germany) was used. In brief, 1
million freshly isolated cells kept on ice in sDMEM (5% FCS) were
resuspended in 100 ll mouse macrophage nucleofactor electroporation
buﬀer (Amaxa), and transfected (program Y-001) with 1 lg of pNF-jB
Luc Vector (Clonetech, Mountain View, CA), and 50 ng of Renilla
pRL-TK vector (Promega, Madison WI). After transfection, cells were
immediately transferred to sDMEM (20% FCS) and cultured in 96-
well plates at 37 C until analysis. Transfection eﬃcacy as measured
by pmaxGFP (Amaxa) was 45%, and cell viability measured by propi-
dium iodide exclusion (Sigma) was 60%. 2 h after transfection cells
were treated with DEX 109 M for 1 h and then stimulated with
LPS 100 ng/ml for 4 h. Luciferase and Renilla activity measured using
the Dual-Luciferase Reporter Assay System (Promega). Relative lucif-
erase activity was normalized to Renilla activity and expressed as the
mean ± S.E.M. of three separate experiments performed in triplicate.
2.6. Electrophoretic mobility shift assay
WT and MIF/ peritoneal macrophages were treated with DEX
109 M for 1 h and then with LPS 100 ng/ml (Sigma–Aldrich) for
30 min. Nuclear extracts were prepared from cultured cells for electro-
phoretic mobility shift assay (EMSA) as described [22,23]. Comple-
mentary oligonucleotides representing the NF-jB kb3 promoter
sequence for TNF [24] were annealed and labeled with 32P
(40000 cpm) using Klenow enzyme. Bands were visualized using a
Phospho-imager (Molecular Dynamics, Sunnyvale, CA, USA),
scanned and densitometry analysed using Image Gauge software (ver-
sion 3.46).2.7. Statistical analysis
Statistical signiﬁcance was assessed for TNF inhibition by ANOVA
(Tukey’s multiple comparison test), EC50 by sigmoidal dose response
(variable slope). In all other experiments Students t test was used
and values of P < 0.05 considered statistically signiﬁcant.3. Results
3.1. MIF deﬁciency increases sensitivity to dexamethasone
To determine the role of endogenous MIF in the regulation
of GC sensitivity, LPS-activated peritoneal macrophages from
wt and MIF/ animals were treated with diﬀerent concentra-
tions of DEX. LPS-stimulated wt cells showed an expected
dose-dependent decrease in TNF release in response to DEX
(Fig. 1A). In contrast, the DEX response curve in MIF/
cells exhibited a left shift with a lower EC50 of 1.25 nM in
MIF/ cells compared with 4 nM in wt (P < 0.0001). This
Fig. 1. Eﬀect of endogenous MIF on DEX sensitivity in LPS-
stimulated peritoneal macrophages. (A). Peritoneal macrophages of
wt and MIF/ mice were treated for 4 h with LPS (100 ng/ml) and
DEX (107–1010 M). The response to DEX is shown as percentage of
LPS-induced TNF. In the absence of MIF, sensitivity to DEX was 3-
fold greater. (EC50 in MIF/ cells = 1.25 nM, wt = 4 nM). One-way
analysis of variance = P < 0.0001, Tukey’s post test for 109 M on
MIF/ and WT = P < 0.001 (**). The results are shown as
mean ± S.E.M. of six independent experiments, performed in dupli-
cate. (B) TNF mRNA expression by wt and MIF/ peritoneal
macrophages stimulated with LPS 100 ng/ml and DEX 109 M for 1 h
is similar. No change is seen at DEX 109 M, where signiﬁcant
diﬀerence in protein expression was detected. The results are shown as
mean ± S.E.M. of three independent experiments.
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sensitivity of approximately 3-fold. The diﬀerence between
MIF/ and wt cells was most apparent at 109 M DEX
(MIF/ vs. wt P < 0.001). This diﬀerence was not accounted
for by reduced TNF release in response to LPS in MIF/
cells, as under these conditions but in the absence of DEX
no diﬀerence in TNF release by LPS-stimulated wt and
MIF/ cells was found (data not shown). Furthermore, no
eﬀect of DEX 109 M on LPS-induced TNF mRNA expres-
sion was observed with in wt and MIF/ cells (Fig. 1B), sug-
gesting post-transcriptional regulation of TNF by DEX and
MIF.
3.2. Increased GC sensitivity in MIF/ cells is not related to
changes in NF-jB activity
We next investigated whether increased GC sensitivity in
MIF/ cells was dependent on changes in nuclear factor
jB (NF-jB) pathway activity. wt and MIF/ peritonealmacrophages were treated with DEX (107–1010 M) for 6 h.
At 109 M, where the diﬀerence of DEX sensitivity of TNF re-
lease was observed, no evidence for diﬀerences in NF-jB inhib-
itor a (IjBa) regulation was detected (Fig. 2A). LPS treatment
produced an expected degradation of IjBa in wt cells. No sig-
niﬁcant diﬀerence in LPS induced IjBa degradation was ob-
served between wt and MIF/ cells (Fig. 2B). The presence
or absence of DEX had no eﬀect on LPS induced IjBa in
either wt or MIF/ cells (Fig. 2B). Importantly, at the con-
centration of DEX (109 M ) which was associated with a sig-
niﬁcant diﬀerence in GC sensitivity, there was no
corresponding diﬀerence in IjBa.
We next examined whether the diﬀerence in DEX sensitivity
was due to a diﬀerence in inhibition of binding of NF-jB to the
TNF promoter. A trend towards reduced LPS-induced NF-jB
binding was seen in MIF/ cells, but this was not signiﬁcant,
and no diﬀerence in the eﬀects of DEX 109 M was seen in
MIF compared to wt cells (Fig. 2C). Luciferase reporter assays
were also used to examine NF-jB pathway activity. Although
a trend towards reduced NF-jB reporter activity was observed
in MIF/ cells, this was again not signiﬁcant, and no diﬀer-
ence between wt and MIF/ cells was observed in the eﬀects
of DEX on NF-jB reporter activity (Fig. 2D).
3.3. Increased GC sensitivity in MIF/ cells is associated with
decreased p38 phosphorylation
Having shown no inﬂuence of endogenous MIF on GC ef-
fects on NF-jB, we next examined LPS-induced JNK, ERK,
and p38 MAPK phosphorylation. In serum-free conditions,
LPS-induced MAPK activation was reduced in MIF/ peri-
toneal macrophages (data not shown). In the serum-supple-
mented conditions under which diﬀerences in GC sensitivity
were observed, no diﬀerence in MAPK phosphorylation was
seen between wt and MIF/ peritoneal macrophages, either
basally or after LPS stimulation (Fig. 3). We next examined
the eﬀect of DEX on LPS-stimulated MAPK phosphorylation.
As increased sensitivity to DEX was seen in MIF/ cells at
109 M DEX, we examined LPS-induced MAPK phosphory-
lation at this concentration of DEX. LPS-activated wt and
MIF/ peritoneal macrophages exhibited similar levels of
JNK (Fig. 3B) and ERK (Fig. 3C) phosphorylation, regardless
of the presence or absence of DEX. In contrast, the addition of
DEX to LPS-activated cells resulted in a signiﬁcant reduction
in p38 phosphorylation in MIF/ cells which was not seen in
wt cells (Fig. 3D).
3.4. Increased GC sensitivity in MIF-deﬁcient cells is associated
with increased expression of MKP-1
The anti-inﬂammatory eﬀect of GC on MAP kinases has
been attributed to dephosphorylation of p38 via induction of
MKP-1 [16]. Given the observation that increased DEX sensi-
tivity in MIF deﬁcient cells was associated with decreased p38
phosphorylation, we next investigated MKP-1 expression in
these cells. MKP-1 expression, as measured by Western blot-
ting, was similar in wt and MIF/ cells under basal and
LPS-stimulated conditions. In LPS-activated MIF/ cells
however, the addition of DEX 109 M was associated with in-
creased MKP-1 expression, an eﬀect not seen in wt cells
(Fig. 4A). The inhibitory eﬀect of endogenous MIF on
DEX-induced MKP-1 expression was conﬁrmed in the absence
of LPS, where DEX 109 M rapidly and signiﬁcantly induced
MKP-1 in MIF/ but not wt cells (Fig. 4B). We next
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accordance with protein levels, no diﬀerence in basal MKP-1
mRNA expression was observed between wt and MIF/ cellsFig. 2. Eﬀects of MIF and DEX on IjBa and NF-jB activity. (A) Peritoneal m
107 M for 6 h. IjBa was measured by Western blotting and the membrane r
independent experiments. At DEX 108 and 107 M increased IjBa expressi
IjBa levels between wt and MIF/ cells was observed. (B) Peritoneal macro
107 M) for 1 h before treatment with LPS 100 ng/ml for 30 min. IjBa was m
loading control. Blots and are representative of three independent experiments
MIF/ cells. DEX induced IjBa expression at both 108 and 107 M in
diﬀerence in IjBa levels was seen between wt and MIF/ cells. (C) Peritone
(109 M) for 1 h before treatment with LPS 100 ng/ml for 30 min, and NF-jB
NF-jB binding in both wt and MIF/ cells. No diﬀerence in the eﬀects of
cells. Blot is a representative of three independent experiments. (D) Perito
multimeric NF-jB luciferase reporter and pre-incubated with DEX (109 M)
jB luciferase activity similarly in wt and MIF/ cells. Treatment with DE
mean ± S.E.M. of three independent experiments, performed in triplicate.(Fig. 4C). However at the concentration of DEX which was
associated with increased GC sensitivity in MIF/ cells,
109 M, induction of MKP-1 mRNA was 2.8-fold higher inacrophages of wt and MIF/mice were incubated with DEX 1010–
eprobed for b-actin as loading control. Blots are representative of three
on was detected in wt and MIF/ cells (,*P < 0.05). No diﬀerence in
phages of wt and MIF/ mice were pre-incubated with DEX (1010–
easured by Western blotting and the membrane reprobed for b-actin as
. LPS induced a signiﬁcant reduction in IjBa expression in both wt and
wt cells, and at 107 M in MIF/ cells (P < 0.05). No signiﬁcant
al macrophages of wt and MIF/ mice were pre-incubated with DEX
binding to the TNF promoter was measured by EMSA. LPS induced
DEX (109 M) on NF-jB binding was seen between wt and MIF/
neal macrophages of wt and MIF/ mice were transfected with a
for 1 h before treatment with LPS 100 ng/ml for 4 h. LPS induced NF-
X 109 M had no eﬀect on NF-jB activity. The results are shown as
Fig. 3. Eﬀect of MIF, LPS, and DEX on MAPK phosphorylation. (A) Peritoneal macrophages from wt and MIF/ mice were incubated with
DEX 109 M for 1 h and stimulated with LPS (100 ng/ml) for 30 min. Phospho-MAPKs were measured by Western blotting and the membranes
were reprobed for b-actin. LPS-activated wt and MIF/ peritoneal macrophages exhibited similar phosphorylation of ERK, JNK and p38.
Preincubation with DEX 109 M for 1 h decreased phosphorylation of p38 in MIF/ cells, however no signiﬁcant change was seen in wt cells. The
result is representative of ﬁve independent experiments. (B–D) Histograms of densitometric analysis (mean ± S.E.M.) of phospho-MAPK Western
blots are shown (P < 0.05 compared to LPS alone).
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concentrations of DEX 107 M produced a similar induction
of MKP-1 mRNA in wt and MIF/ cells. This indicates a
left shift in DEX sensitivity of MKP-1 expression in the ab-
sence of endogenous MIF.
3.5. Exracellular rMIF reduces MKP-1 expression
To investigate whether blocking of extracellular MIF in wt
cells replicated the eﬀect of MIF deﬁciency on DEX sensitivity
of MKP-1 expression, we co-incubated wt cells with anti-MIF
mAb (200 lg/ml) and DEX 109 M for 1 and 6 h. No diﬀer-
ence in MKP-1 expression was seen (Fig. 5A), suggesting that
regulation of DEX-sensitivity of MKP-1 by MIF in wt cells
could not be modiﬁed by neutralising extracellular MIF in
short term culture. We investigated whether restoration of
MIF in MIF/ cells induced a corresponding decrease in
MKP-1 expression. In the presence of rMIF, MKP-1 mRNA
expression in DEX-treated MIF/ cells was strongly and
dose dependently suppressed (P < 0.05) (Fig. 5B). This eﬀect
of rMIF could be fully inhibited by anti-MIF mAb
(Fig. 5B), indicating that extracellular MIF participates in
the regulation of DEX-induced MKP-1.4. Discussion
The current data provide direct evidence that the absence of
endogenous MIF increases sensitivity to GC. We found that
lower concentrations of DEX were required to inhibit LPS-in-duced TNF release in MIF deﬁcient cells compared to cells
expressing MIF. Previous studies have reported reduced
LPS-induced TNF in MIF/ cells [17], and in serum-free
conditions we have conﬁrmed this observation (data not
shown); in the serum-supplemented culture conditions re-
ported here, however, we observed no diﬀerence in LPS-
induced TNF release between wt and MIF/ cells in the
absence of DEX. These conditions were chosen in order to iso-
late the eﬀect of MIF on DEX-mediated changes in TNF.
Induction of TNF in monocytes and macrophages by pro-
inﬂammatory stimuli has been shown to be transcriptionally
and post-transcriptionally regulated [24,25]. LPS, a potent in-
ducer of TNF expression works through a mechanism highly
dependent on NF-jB and the jB sites in the TNF promoter
[26,27] as well as through post-transcriptional regulation by
p38 [25]. p38 regulates TNF gene expression by phosphoryla-
tion of MAPK-activated protein kinase (MAPKAPK) 2 [28].
A recent study from Roger et al. found similar involvement
of MIF in the regulation of MKP-1 expression [29], however as
MIF anti-sense was used as opposed to primary MIF/ cells,
these ﬁndings require conﬁrmation. We have also extended
these observations to deﬁne a MIF-regulated eﬀect of DEX
on p38 MAP kinase phosphorylation, Unlike Roger et al.,
we detected no diﬀerence in DEX eﬀects on NF-jB activation
using multiple modalities; these ﬁndings are in keeping with
previous reports which failed to show an eﬀect of MIF on
the NF-jB pathway [30,31]. Direct eﬀects of recombinant
(r)MIF on NF-jB pathway molecules have been reported
[32], and Daun et al. reported evidence for MIF reversal of
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iological concentrations of rMIF on NF-jB nuclear transloca-
tion was found in that study, or in similar studies in human
ﬁbroblast-like synoviocytes [30] or other cell types [31]. Eﬀects
of MIF on the activation of p38 MAP kinase have been previ-
ously reported [9], but a role for MIF in the regulation of GC-
mediated inhibition of p38 MAP kinases has not beenFig. 4. Eﬀect of MIF on MKP-1 expression. (A) Peritoneal
macrophages of wt and MIF/ mice were incubated with DEX
109 M for 1 h and stimulated with LPS (100 ng/ml) for 30 min.
Similar increased expression of MKP-1 protein was observed after LPS
stimulation in wt and MIF/ cells. In the presence of DEX increased
expression of MKP-1 was seen in MIF/ but not wt cells (P < 0.05).
The results are shown as mean ± S.E.M. of ﬁve separate experiments.
(B) Peritoneal macrophages of wt and MIF/ mice were incubated
with DEX 109 M for 1 and 6 h. Signiﬁcant induction of MKP-1
expression was seen in MIF/ cells at 1 and 6 h. The blot is
representative of four independent experiments. The histograms are
shown as mean ± S.E.M. of four independent experiments. (P < 0.05
for DEX-treated MIF/ cells compared to untreated MIF / cells,
**P < 0.001 and *P < 0.05 for MIF/ compared to wt cells). (C) No
diﬀerence was observed in basal MKP-1 mRNA between wt and
MIF/ cells. The results are shown as mean +/ S.E.M. of three
separate experiments. (D). Peritoneal macrophages of wt and MIF/
mice were incubated with DEX 109 M for 1 h. Expression of MKP-1
mRNA was induced by DEX 109 M in MIF/ but not wt cells
(*P < 0.05). DEX 107 M induced MKP-1 mRNA expression similarly
in MIF/ and wt cells. The results are shown as mean ± S.E.M. of
three separate experiments.
b
Fig. 5. Eﬀect of extracellular MIF on DEX induced MKP-1 expres-
sion. (A) WT peritoneal macrophages were incubated with DEX
109 M, MIF mAb or control IgG1 for 6 h. No diﬀerence was
observed. (B) Peritoneal macrophages of MIF/ mice were treated
for 1 h with DEX 109 M in presence or absence of rMIF (1–100 ng/
ml). Results are shown as the percentage of DEX induced MKP-1
mRNA. MIF dose-dependently inhibited MKP-1 expression induced
by DEX. The results are shown as mean ± S.E.M. of three separate
experiments. (*P < 0.05). The addition of anti-MIF mAb but not
control IgG1, prevented the eﬀects of rMIF on DEX-induced MKP-1
expression.
980 D. Aeberli et al. / FEBS Letters 580 (2006) 974–981previously described. Given the known importance of p38
MAP kinase to inﬂammatory disease, the current data suggests
a functionally signiﬁcant interaction between MIF and GC.
Dexamethasone regulates TNF transcription either by glu-
cocorticoid receptor (GR)-dependent interactions with the
p65 NF-jB subunit and AP-1 binding site [34], or induction
of IjBa synthesis [35]. Post-transcriptional regulation of
TNF expression by GC is mediated through GR dependent
expression of MKP-1 [15,16]. MKP-1 dephosphorylates p38
MAPK [16,36], which is involved in post-transcriptional reg-
ulation of TNF expression via mRNA stabilisation [28].
DEX has been previously shown to regulate TNF expression
by inhibition of p38 activation and increased MKP-1 expres-
sion, without changes in transcriptional regulation of TNF
[16,28].
In our study, no direct evidence of eﬀects of endogenous
MIF on transcriptional regulation of IjBa by DEX was ob-
served. Furthermore, no diﬀerence in DEX eﬀects on binding
of NF-jB in the TNF promoter was seen in the presence or ab-
sence of endogenous MIF, consistent with the lack of a change
in TNF mRNA. These results diﬀer from previous reports,
where reversal of DEX inhibition of NF-jB by rMIF was ob-
served [29]. We propose that this reﬂects the use in the current
study of primary MIF-deﬁcient cells, as opposed to exogenous
recombinant human MIF and cell lines.
The observation of DEX induction of MKP-1 in MIF/
cells at the same concentration at which the change in DEX
sensitivity was most apparent strongly suggests an association
between MKP-1 induction and DEX responsiveness. MIF/
cells showed higher expression of MKP-1 and corresponding
reduced levels of phospho-p38 MAP kinase compared to
wt cells in the presence of LPS and DEX. Dose dependent
reversal of DEX induced MKP-1 by rMIF, and inhibition of
conditioned medium eﬀects on MKP-1 by anti-MIF mAb,
conﬁrm the regulatory eﬀect of MIF on GC-induced MKP-1
expression.
The associated ﬁnding of increased GC sensitivity and in-
creased MKP-1 in the complete absence of MIF, or as recently
shown in a partially MIF deﬁcient system achieved through
the use of anti-sense [29], suggest that MIF regulation of
MKP-1 expression represents a central process through which
GC sensitivity of LPS-induced TNF expression is mediated.
Given the recent report that MIF overexpression is associated
with altered GC sensitivity in humans with renal inﬂammation
[37], the current results shed light on the subcellular mecha-
nism of regulating GC sensitivity in humans therapeutically.
Should the initial observations in humans be conﬁrmed in fur-
ther studies, a strong case for MIF antagonism in the search
for ‘steroid-sparing’ therapy will have been made.
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